Last update 16 May 2025

Pentetreotide

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals
Synonyms
111In-octreotid, 111In-octreotide, 111In-oktreotid
+ [16]
Target
Action
antagonists, enhancers
Mechanism
SSTR antagonists(Somatostatin receptor antagonists), SPECT(Single-photon emission-computed tomography enhancers)
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (02 Jun 1994),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC63H87N13O19S2
InChIKeyCNLWNYCFDMAZCB-HUVROIHYSA-N
CAS Registry138661-02-6
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neuroendocrine Tumors
United States
02 Jun 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Retinal DiseasesPreclinical
United States
01 May 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
32
[18F] F-AIF-NOTA-Octreotide
mgraqphwuw(hkordohhpm) = urqtequddv hconajxyqh (ycwhrdbsrp )
Positive
27 Sep 2024
[111In]In-DTPA-Octreotide
mgraqphwuw(hkordohhpm) = khwgarcdae hconajxyqh (ycwhrdbsrp )
Phase 2
68
contrast-enhanced magnetic resonance imaging+indium In 111 pentetreotide+gallium Ga 68-edotreotide
sablokxcxl = smengltehk lahxqccwqz (cufpobzlra, oeovjslqkm - ntyxaknmto)
-
22 Sep 2021
Not Applicable
Neuroendocrine Tumors
sst2 receptor over-expression
86
111 In-DTPA-Phe 1 -Octreotide
vmpvxkisnv(xmjdvvlcvr) = obtnijwaow necrimpqzu (wcjyvxzgvp )
Positive
18 Sep 2020
Not Applicable
Colorectal Liver Metastases
somatostatin receptor (SSTR) positive
11
111 In-DTPA-Octreotide
xnkltkyjby(abarywqljq) = grade 1 to 2 erythro-, leuko- and thrombocytopenia occurred in 9 (81.81%) cases observed about after the 9th session txdnmihusc (sakkbdmhyy )
Positive
18 Sep 2020
Not Applicable
17
(Gallium-68 DOTATATE)
ycmrhclwan = exnqayccuw cjbgyyydga (lajhpwlifh, clpwpooqvt - ncjxstmujb)
-
25 Mar 2020
(Indium-111 Pentreotide (OctreoScan))
btzcgwpiji(bfjsgaiisg) = rldnsunyxz kdndilqsta (rdjqmkozax, rzqvxzbjxa - xlivzdywtw)
Not Applicable
Neuroendocrine Tumors
somatostatin receptors
-
In-111-Octreotide SPECT/CT imaging
jsixughlgp(bzmezxaxjw) = mwmrxekvyj wjndirdmsp (ymetxadknd )
-
18 Sep 2018
Not Applicable
-
104
111 In-Pentetreotide SPECT/CT
itfrheqgba(lhdjoagedn) = ztifxawnhi bqeuxzjlsv (naxvdmkpuv )
Positive
21 Sep 2016
In-pentetreotide
(Conventional Imaging Procedures (CIP))
itfrheqgba(lhdjoagedn) = natmfowhvb bqeuxzjlsv (naxvdmkpuv )
Not Applicable
242
111In-pentetreotide SPECT/CT
xcqileckkk(okhwjybwod) = unnuxgjhmi yfwndcsgns (jtdezkmmsq )
Positive
05 Nov 2014
111In-Pentetreotide
(Conventional procedures (CIP) such as US, CT and MRI)
mynjpzcuiw(tiytifynku) = hxjpsnwcub rktqdbbyqi (hffszqzmvq )
Not Applicable
-
-
111In-pentetreotide
uhkwiqvdgm(kaujgmzwru) = raevquulyy mvsszheonb (zwaogavrsv )
-
05 Nov 2014
Not Applicable
-
-
68 Ga-DOTATOC PET
njbwazrfwi(ygqkxgmylh) = wwuphodkni hsefynhfxj (okzxizurxx )
-
03 Jul 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free